Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Aprazer Healthcare Pvt Ltd
120 Tablets
Abiraterone Acetate
Keep in cold place
Delivering To:
Overview
Abirakast 250mg Tablet belongs to the category of anti-androgens. This medicine used in the treatment of prostate cancer. It has an active ingredient Abiraterone Acetate which works by blocking the production of testosterone and other hormones that are responsible for the growth and spread of cancer cells from the prostate gland to other parts of the body. It is available with a fixed strength of 250 mg as tablets for oral administration only.
Prostate Cancer
Prostate Cancer
Like any other anticancer medicine, Abirakast 250mg Tablet also shows some side effects, which vary from one person to another according to various health factors. Most of them are mild, and some are serious enough to need immediate medical attention.
Some common side effects include:
Diarrhea
High blood pressure
Cough
Joint swelling
Nausea
Hot flashes
Headache
Increased glucose level in the blood
Edema (swelling)
Vomiting
Decreased potassium level in the blood
Fatigue
Anemia (low number of red blood cells)
Urinary tract infection
Seek medical attention in case of any unusual or severe side effects immediately.
Take Abirakast 250mg Tablet in the dosage and duration exactly as prescribed by the doctor. The medicine should be taken orally on an empty stomach or can be consumed one hour before or two hours after a meal. In case of an overdose, contact your doctor immediately.
Abirakast 250mg Tablet is an anticancer medicine prescribed to treat prostate cancer. It works by blocking the action of CYP17 enzyme to stop the production of male hormones that are responsible for the prostate cancer. In this way it slow down or stop the uncontrolled growth of cancer cells effectively.
Alcohol
unsafe
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Abirakast 250mg Tablet.
Pregnancy
risky
Do not take Abirakast 250mg Tablet during pregnancy, as it is a highly unsafe medicine for the fetus. Also, this medicine is especially designed to treat male-related cancers.
Breast Feeding
risky
Abirakast 250mg Tablet is unsafe to use during breastfeeding as it may cause toxicity to the baby. Also, this medicine is especially designed to treat male-related cancers.
Driving
risky
Abirakast 250mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.
Kidney
caution
Consumption of Abirakast 250mg Tablet should be avoided without informing the doctor if you have any kidney-related issues.
Liver
caution
Consumption of Abirakast 250mg Tablet should be avoided without informing the doctor if you have any liver-related issues.
Abirakast 250mg Tablet is an anticancer drug which work by managing the symptom & slowing down or controling the growth of cancer cells in the case of prostate cancer. However this medicine can't cure prostate cancer completely.
Some common side effect of Abirakast 250mg Tablet include diarrhea
, high blood pressure, cough, joint swelling, nausea, hot flashes, headache, increased glucose level in blood, etc.
It is advisable to avoid driving and operating heavy machinery asAbirakast 250mg Tablet may cause dizziness.
No it is not a chemotherapic drug it is a hormone therapy based anticancer medicine which manage cancer by controling the prodcution of responsible hormone.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
1.Flaig, T. W., Plets, M., Hussain, M. H., Agarwal, N., Mitsiades, N., Deshpande, H. A., ... & Thompson, I. M. (2017). Abiraterone acetate for metastatic prostate cancer in patients with suboptimal biochemical response to hormone induction. JAMA oncology, 3(11), e170231-e170231.
2.Chi, K. N., Spratlin, J., Kollmannsberger, C., North, S., Pankras, C., Gonzalez, M., ... & Tran, N. P. (2015). Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer. The Journal of Clinical Pharmacology, 55(12), 1406-1414.
3.Shah, S., & Ryan, C. J. (2009). Abiraterone acetate. Drugs of the Future, 34(11).
4.Gonçalves, B. F., de Campos, S. G. P., Fávaro, W. J., Brandt, J. Z., Pinho, C. F., Justulin, L. A., ... & Scarano, W. R. (2018). Combinatorial effect of abiraterone acetate and NVP-BEZ235 on prostate tumor progression in rats. Hormones and Cancer, 9(3), 175-187.
5. Taheri, A., Almasri, R., Wignall, A., Schultz, H. B., Elz, A. S., Ariaee, A., ... & Prestidge, C. A. (2024). Enhancing the pharmacokinetics of abiraterone acetate through lipid-based formulations: addressing solubility and food effect challenges. Drug Delivery and Translational Research, 1-13.
Aprazer Healthcare Pvt Ltd
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.